R ed blood cell (RBC) exchange is a wellestablished therapy for sickle cell disease (SCD) and other diseases for which RBCs are implicated in the pathogenic process, in both acute and chronic settings. 1 Some form of vascular access is required, and several factors must be considered for the optimal treatment of the patient. 2 This decision itself depends on the selection of the most appropriate modality for removal and/or replacement of RBCs, including automated RBC exchange, partial manual exchange, and simple transfusion. 3, 4 Complications are common and can be attributed to both the exchange modality and the vascular access used. 3, 5 In this review, we discuss reported indications for RBC exchange, considerations for selecting the most appropriate exchange modality, vascular access options, and recommendations for the appropriate care and prevention of risks associated with vascular access.
INDICATIONS FOR RBC EXCHANGE
Several diseases are potentially amenable to treatment by RBC exchange and are discussed below in the context of acuity and further subgrouped by etiology. Table 1 summarizes these indications and includes recommendations by the American Society for Apheresis (ASFA).
Acute indications for RBC exchange Infection
RBC exchange in patients with babesiosis and malarial infection can rapidly reduce parasitemia and is generally well tolerated. 1, [6] [7] [8] However, rebound increase in parasite burden can occur. 9, 10 A group at the Centers for Disease
Control and Prevention who analyzed available data in 2013 did not recommend RBC exchange based on the lack of evidence showing efficacy with regard to outcomes despite demonstrated rapid parasite clearance times. However, ASFA disputed those findings by pointing out variations between approaches and continues to support the use of RBC exchange for severe malaria on an individual basis. 1, 11, 12 ASFA recommends RBC exchange as a second-line therapy for babesiosis, especially when parasitemia is above 10% or significant comorbidities are present. 1 transfusion requirements. 1 Factors potentially contributing to variable success include the timing and efficiency of target RBC replacement; therefore, this indication is considered on an individual basis. 1 
Prevention of RhD alloimmunization after RBC exposure
The risk for development of anti-D antibodies in D antigen-negative individuals after exposure to D antigenpositive RBCs and its consequences, especially in women of childbearing age, are well documented. Case reports describe situations in which individuals were exposed to D-incompatible blood, and RBC exchange was performed with subsequent Rh immunoglobulin administration. No development of anti-D was observed, including in one woman who later delivered a D antigen-positive infant without complication. Although promising, RBC exchange for preventing clinically significant alloimmunization should only be considered in the clinical context of the patient, including exposure volume, child-bearing potential, and risk for alloimmunization.
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Erythropoietic porphyria with liver disease
Limited evidence suggests that RBC exchange, potentially combined with therapeutic plasma exchange, could decrease blood and plasma protoporphyrin levels. The clinical utility is questionable, because case reports suggest that decreased protoporphyrin levels may not necessarily translate into significant changes in liver function;
however, it can be used on a case-by-case basis as clinically warranted.
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Sickle cell disease
In SCD, a point mutation results in a single amino acid change (valine to glutamic acid) at residue 6 of the bglobin protein, resulting in abnormal hemoglobin S (HbS) that polymerizes under deoxygenating conditions. RBCs in patients with SCD are less deformable, increase blood viscosity, and undergo hemolysis, all of which can contribute to microvascular occlusion and other mechanisms involved in SCD complications (discussed below). The major rationale for RBC exchange in SCD is to replace the patient's RBCs with donor RBCs, which mitigate the pathophysiology of SCD and may reduce erythropoietic drive. 1 In the Stroke Prevention Trial in Sickle Cell Anemia (STOP trial), RBC transfusion was deemed an effective strategy to prevent first stroke and has since become a mainstay of therapy for this indication.
14 Later, a retrospective cohort study demonstrated a five-fold increase in the risk for second stroke in those who received simple transfusion versus RBC exchange after their first stroke. 15 Retrospective studies have shown some success in demonstrating the safety and efficacy of RBC exchange for the treatment of acute chest syndrome. 1, 16, 17 Limited evidence suggests that RBC exchange could be beneficial to patients with acute and recurrent episodes of priapism who fail other therapies. 18 Case reports also suggest that RBC exchange potentially could be lifesaving in patients who have multiorgan failure and intrahepatic cholestasis.
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Other acute indications RBC exchange reportedly has been used in other clinical scenarios in which RBCs are determined to be the primary cause of clinical symptoms, and replacement could change the disease course. Examples include toxicity due to tacrolimus and sirolimus; drugs that are highly bound to RBCs, as well as carbon monoxide poisoning and severe acquired methemoglobinemia. [23] [24] [25] [26] [27] Mitigation of delayed hemolytic transfusion reactions has also been described, in which RBC exchange was used to remove potential RBC targets of hemolysis with clinical improvement. 28, 29 These reports are examples of the potentially expanding role for RBC exchange in medicine, although more data are required before such indications merit official recommendations.
Nonacute/chronic indications for RBC exchange in sickle cell disease
To date, indications for nonemergent and long-term RBC exchange are primarily only for patients with SCD and are reviewed below.
Stroke prophylaxis and iron-overload prevention
Long-term management of SCD is currently the only chronic indication for RBC exchange. 1, 30, 31 After the pivotal Stroke Prevention Trial in Sickle Cell Anemia (STOP trial), the STOP 2 trial demonstrated that discontinuing prophylactic transfusion resulted in the reversion of abnormal arterial blood flow rates, indicating a high risk for stroke, cementing the need for indefinite chronic transfusions in this patient population. 14, 32 Further analysis demonstrated correlation with an increased risk of silent cerebral infarction (SCI), reinforcing the idea that transfusions also help to mitigate subclinical sequelae of SCD. 33 In the Silent Cerebral Infarct Multi-Center Clinical Trial (SIT), children who had evidence of SCI but no neurological deficits were randomized to undergo observation (standard of care) or regular RBC transfusions. Children who received regular transfusions had significantly fewer additional SCIs, suggesting a larger role for transfusions and/or RBC exchange in the prevention of SCIs. 34 Iron overload is a known serious complication of chronic RBC transfusions. A retrospective study showed that regular RBC exchange with concurrent iron chelation therapy resulted in a greater reduction of ferritin levels and liver iron concentrations compared with simple transfusion or partial manual exchange. 35 
Vaso-occlusive pain crises
Data are sparse on the utility of RBC exchange for vasoocclusive pain crises. One group in a developing country noted that manual partial RBC exchange was tolerated and at least partially successful in reducing symptoms for both acute and chronic complications of SCD, including persistent vaso-occlusive crises. 36 
Operative management
Patients with SCD often have complications warranting surgical intervention; however, the condition itself places them at higher risk in the perioperative period. A recent multicenter, randomized controlled trial indicated that the incidence of serious complications among patients undergoing elective low-risk and medium-risk surgeries, including joint replacements, was lower in those who received preoperative transfusions, including a significant reduction in the occurrence of acute chest syndrome, suggesting the possible utility of preoperative transfusion in this setting. 37 
Pregnancy
A systematic review and meta-analysis revealed a correlation between prophylactic RBC transfusions in pregnant women with SCD and reduced maternal complications, such as mortality, vaso-occlusive episodes, pulmonary complications, pulmonary embolism, and pyelonephritis. 38 Reduced fetal complications, such as preterm births and neonatal deaths, also were observed. 38 Overall, RBC exchange has proven to be a useful therapeutic option for diseases involving RBC pathophysiology. The approach to accessing the patient's blood and the manner in which the procedure is performed depend on numerous factors, including the acuity of the clinical situation, the condition of the patient, the disease entity being treated, and access to health care resources, among others, as further explained below.
RBC EXCHANGE TREATMENT CONSIDERATIONS RBC exchange: Modalities
For diseases in which RBC exchange is indicated, both automated and manual modalities may be considered. Automated RBC exchange involves the use of an extracorporeal device that separates RBCs from the rest of the patient's whole blood by centrifugation and mixes the remaining blood fractions with donor RBCs before they are returned to the patient. Details on these devices are described below. Partial manual RBC exchange involves the removal of whole blood by phlebotomy followed by intermittent transfusion of donor RBCs. In addition to these two modalities, simple transfusion of RBCs without phlebotomy, although not an exchange procedure per se, may be useful for several indications. For indications other than SCD, automated RBC exchange is usually preferred, because the goal is to reduce pathogenic RBCs as quickly and efficiently as possible. For patients with SCD, however, all three modalities offer benefits and downsides, and the most appropriate selection must be considered carefully for each patient's situation. In acute situations, the efficacy of the modality should be balanced against the urgent need for therapy. Very anemic patients (<7 g/dL hemoglobin) with emergent complications, such as stroke, may benefit the quickest from simple transfusion, because the time needed to prepare for automated RBC exchange, including preparation of vascular access, may lead to additional clinical consequences. Patients with higher hemoglobin concentrations, such as those with hemoglobin SC disease, may still require RBC exchange, because simple transfusion may exacerbate disease by increasing intravascular viscosity or by causing volume overload. 1 Retrospective studies have indicated that both RBC exchange and simple transfusion are equally effective in treating acute chest syndrome in both children and adults, although the choice of modality in those studies may have been biased by patient presentation. 16, 17 However, the degree of reduction in sickled RBCs is preferentially much greater with RBC exchange. When selecting a transfusion modality for patients with SCD who require transfusion therapy on a chronic basis, many factors should be considered. These patients typically receive transfusions every 4 to 8 weeks on an indefinite basis and thus are susceptible to the adverse effects of long-term and/or intermittent vascular access, as well as complications caused by the sheer number of transfusions, including RBC alloimmunization and iron overload. It is also important to be sensitive to the effects that periodic therapy will have on the patient's lifestyle, including, but not limited to, maintenance of vascular access. Most patients begin chronic RBC exchange therapy as children; therefore, the optimal choice of vascular access may change as they grow into adolescence and adulthood.
In a recent survey, it was found that simple transfusion tends to be preferred over automated RBC exchange transfusion in children (52% vs. 37%) but is preferred less in adults (30% vs. 52%), with manual exchange being the least preferred method in both groups. 3 The most commonly cited barriers to RBC exchange were vascular access and limited access to equipment and personnel. 3 In addition to direct vascular complications, which are discussed in a later section of this review, the risk of nonvascular complications may significantly influence the choice of transfusion modality and thus indirectly affect the choice of vascular access. RBC alloimmunization is very common in patients with SCD who receive chronic transfusions (range, 18%-76% without extended antigen matching) and may make future exchanges more difficult. 5 RBC exchange requires more units per treatment and thus higher donor exposures than simple transfusion (3.7 times on average); however, surprisingly, it results in equivalent or fewer instances of alloimmunization (0-0.16 antibodies/100 units vs. 0.14-1.16 antibodies/100 units).
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Iron overload is a common complication of simple transfusion regimens for chronic therapy. 42, 43 It is often severe enough to require iron chelation. Because automated RBC exchange removes older RBCs from the patient's system, it is less likely to cause iron overload and may even reduce iron overload in patients who previously received treatment on a simple transfusion regimen.
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Patients who do not benefit from or are not compliant with iron chelation may be better served by being switched to automated exchange. In a comparison of costs associated with chronic transfusion therapy, automated exchange incurred more direct costs than simple transfusion (due to equipment costs, units of blood, etc.) but overall was less expensive because of the added costs of chelation therapy needed for patients on simple transfusion regimens. 3 Less data are available comparing manual exchange transfusion with the other modalities, but it is generally believed that the benefits and risks of manual exchange transfusion are intermediate between those of automated exchange and simple transfusion. A single-center study demonstrated that manual exchange transfusion is as effective at meeting HbS targets as automated exchange and results in dramatically fewer catheter complications. 4 Isovolemic hemodilution-RBC exchange is a modification of automated exchange in which isovolemic hemodilution with saline or albumin is performed before RBC exchange. This allows the use of fewer RBC units but reportedly has been associated with higher rates of some adverse events, including citrate and vasovagal reactions. 44 Its use has not yet been widely adopted.
On balance, automated RBC exchange is associated with lower costs and fewer nonvascular adverse events. However, vascular access is an important barrier to RBC exchange that must be weighed against these benefits.
Automated RBC exchange: Devices and technique
The RBC exchange devices available in the United States are centrifugation-based; they rely on the density of blood constituents for separation, whereby centrifugation of whole blood results in layers, with RBCs forming the bottom layer. The most commonly used devices are the COBE Spectra and the Spectra Optia (both from Terumo BCT), the latter of which was approved by the US Food and Drug Administration for RBC exchange in January 2014 and is expected to replace the COBE Spectra. 45, 46 This newer instrument provides touch-screen controls, and its centrifuge interface adjustments are automated through high-speed images compared with the manual adjustments required for the COBE. Both instruments operate by continuous-flow centrifugation, whereby blood withdrawal, centrifugation, removal of the patient's RBCs, and reinfusion of the rest of the blood components with the replaced RBCs are all performed in an ongoing manner. 47 The centrifuge is the functional unit of the apheresis instrument; it spins at high speeds of 2000 to 2500 revolutions/minute to separate the components of the anticoagulated blood based on their specific gravity (density). The densest blood components are the RBCs (specific gravity, 1.078-1.114), and they collect at the farthest point from the axis of rotation. The least dense component is plasma (specific gravity, 1.025-1.029), and it is collected closer to the axis. 48 The efficiency of separation of different blood components depends on the radius and rotation speed of the centrifuge. It also depends on the dwell time, which can be increased by decreasing the inlet flow rate, thus giving blood more time in the centrifuge to separate. 49 Citrate is the most common anticoagulant used in apheresis procedures, including RBC exchange. Citrate inhibits the calcium-dependent coagulation cascade by binding to calcium ions. It effectively anticoagulates the blood as it mixes with the removed blood before it enters the centrifuge. Citrate is actively metabolized by the liver, kidneys, and skeletal muscles and is diluted throughout the body. Citrate can induce transient symptomatic hypocalcemia, which warrants calcium supplementation. Citrate toxicity might occur at an increased frequency with RBC exchange relative to other apheresis procedures, predicated on the citrate load from multiple RBC units over relatively short procedure duration. The usual bloodto-anticoagulant ratio is 13:1, but this ratio can be adjusted manually if needed. 50 The patient's weight, height, sex, and hematocrit value are required for the instrument to calculate the total blood volume and the RBC volume. Other parameters required for RBC exchange are a desired post-procedure hematocrit and the patient's fraction of cells remaining (FCR). For SCD, FCR is calculated based on the patient's current HbS percentage (cHbS) and the desired HbS percentage (dHbS) using the following equation: FCR 5 dHbS/cHbS 3 100%. The goal of RBC exchange in SCD is to leave the patient with a hematocrit of approximately 30% and an HbS of 30% or less. 51, 52 An FCR of 30%
will leave the patient with a post-procedure HbS of 30% if the cHbS is 100%, which may be considered in patients who present with acute crises in whom the pre-exchange HbS is unknown. However, for procedures in which the pre-exchange HbS is known, this value will be used to calculate the goal FCR. RBCs are only present intravascularly, and their removal rate is quite efficient in RBC exchange compared with the rate in other therapeutic apheresis procedures targeting substances that can equilibrate between the intravascular and extravascular compartments. 53 An exchange of little more than one patient RBC volume will leave the patient with an FCR of 30%. It should be emphasized that overcorrecting the hematocrit will increase blood viscosity, which can result in decreased oxygen delivery. Thus it is not ordinarily recommended to increase desired hematocrit above 30% in patients with SCD, especially in the setting of urgent procedures for acute chest syndrome. The target post-procedure hematocrit and FCR can only be achieved accurately if HbS-negative RBC units are used for the exchange; thus, RBC units should be screened for sickle cell trait. The donor units should be ABOcompatible and Rh-compatible, leukoreduced, and preferably negative or phenotype-matched for C, E, and K antigens to reduce the risk of alloantibody formation, depending on the urgency of the procedure. Some centers prefer to use fresh RBC units (<7 days old) to provide immediate 2,3-diphosphoglycerate and maximize the survival time of RBCs; however, this practice is not universal.
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VASCULAR ACCESS: TYPES AND COMPLICATIONS
Although RBC exchange is relatively safe and well tolerated, vascular access-related issues may present a major barrier to RBC exchange continuation, highlighting the need for better options for improved central and peripheral access. 55 A recent retrospective study demonstrated that, although iron loads were lower in patients undergoing chronic RBC exchange, there were increased complications associated with vascular access. 4 Undoubtedly, there are potential benefits of RBC exchange; however, there are possible deleterious clinical consequences for patients who need RBC exchange but for whom vascular access is limited or difficult to maintain. This warrants further discussion so clinicians can be prepared to approach situations involving vascular access as it relates to RBC exchange to ensure optimized care.
Peripheral access
RBC exchange, like all therapeutic apheresis procedures, requires reliable vascular access to achieve adequate inflow and outflow rates. The blood flow from the patient into the instrument has to be steady, and the patient's vascular access site and catheter must tolerate high negative pressure without collapsing. In addition, the access returning blood from the instrument to the patient should be large and capable of tolerating high positive pressure. Peripheral venous access is often adequate for RBC exchange and is preferred over central venous catheters (CVCs), because the complication rate is lower. The antecubital veins are typically suitable for withdrawal and return. In general, a 16-gauge to 18-gauge needle is used for blood withdrawal, whereas a 19-gauge to 20-gauge needle is used for the return. 
Short-term CVCs
A temporary dual-lumen CVC can be used for patients without suitable peripheral veins and for those who present with an acute event requiring hospital admission for monitoring, hydration, and/or pain management. The catheter should have at least two access lines and be rigid enough to withstand high pressures and flow rates. A vascular access device should allow rapid insertion for immediate availability and show high biocompatibility and low risk of infection. 56 The choice of placement site depends on the expected duration of treatment, operator experience, risk of complications, and anatomical conditions. 56, 57 Subclavian or internal jugular (IJ) venous catheters are generally preferred over femoral venous catheters because of their decreased risk for infection, and IJ catheters are generally preferred over subclavian catheters due to a lower risk of serious complications. Table 2 summarizes the advantages and disadvantages of using subclavian, IJ, and femoral venous catheters. For anatomic reasons, right-sided catheters are generally preferred over left-sided catheters. The right IJ vein has a wider diameter and runs more superficially than the left IJ vein; this makes a right-sided approach more acceptable than a left-sided one for CVC insertion, because it reduces the risks of vessel perforation and thrombosis. 58 A right subclavian vein approach for catheter insertion is also superior to a left subclavian vein approach, because it is associated with fewer complications and insertion failures. 59 CVC insertion is performed under aseptic conditions. The use of chlorhexidine (rather than alcohol or iodine) is preferred, because it substantially reduces the incidence of catheter-related infections. 60 Bleeding risks and disorders should be addressed before catheter insertion.
A post-insertion thoracic x-ray will confirm the correct catheter tip position in the superior vena cava or right atrium and can detect pneumothorax and kinking. The use of a Doppler or ultrasound device to perform central venous cannulation is recommended. Studies have shown that using ultrasound guidance in IJ vein cannulation improves the success rate and reduces complications. 61 CVCs can be accessed immediately after insertion, which makes them the best choice for urgent RBC exchange.
Tunneled catheters and implanted ports
Outpatients requiring frequent RBC exchange over long periods of time can receive tunneled venous catheters or implanted subcutaneous ports. Tunneled catheters are placed by surgeons or interventional radiologists. They are passed under the skin from the insertion site to a separate exit site; thus, they provide stability and are less prone to infection. The catheter needs regular flushing. Implanted ports are placed entirely under the skin, making the risk of infection lower. These ports are surgically placed just beneath the clavicle and run under the skin into the subclavian or IJ vein. 62 The port can be accessed through a small reservoir that has a membrane on one side for the needle insertion or accessed directly using an intravenous catheter. Accessing the port is obtained with special noncoring needles, which go through the skin and the port membrane into the reservoir. These ports are cosmetically convenient to patients and allow them to bathe and swim, activities restricted by externally exiting catheters. Maintenance flushing of the port is recommended monthly when the port is not accessed. 63 All catheters should be locked after each apheresis procedure with heparin or sodium citrate to prevent clotting. Single-lumen and double-lumen ports are available. If a single-lumen port is used for RBC exchange, then blood will be withdrawn from the port and returned through a peripheral vein, or vice versa. The use of these implanted ports may be limited due to the complexity in accessing them and the need for certification and experience among apheresis nurses and operators. Several manufacturers produce apheresis-compatible CVCs and ports, including AngioDynamics, Bard Access Systems, and Quinton Instrument.
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Arteriovenous fistulae
The use of arteriovenous (AV) fistulae in patients with SCD is not common because of the risk of complications, including thrombosis. In a recent cohort of 26 patients with SCD undergoing RBC exchange through an AV fistula, 19 (73%) had thrombotic, stenotic, or infectious complications of their fistulae. 65 However, AV fistulae are considered the best vascular access option for patients undergoing hemodialysis. 66 In addition, AV fistulae are associated with lower rates of complications compared with tunneled CVCs in patients undergoing hemodialysis. 67 
Peripherally inserted central catheters
Peripherally inserted central catheter lines are problematic and unsuitable for RBC exchange, because the primary access for blood withdrawal does not support the high flow rates in apheresis.
Choice of vascular access
The decision regarding vascular access in RBC exchange is multifactorial, depending on the urgency and frequency of treatment, the availability of peripheral venous access, and the patient's vascular anatomy and underlying disease state. RBC exchange, as with all centrifugation-based therapeutic apheresis, runs efficiently at blood flow rates less than 100 mL/minute. 68 Peripheral veins generally withstand this blood flow rate, and they should be the first choice for vascular access whenever possible because of the low rate of complications. 2, 68 Important determinants of successful peripheral access include a short duration of treatment, the experience of the nursing staff, and the ability of the patient to actively participate should the need arise. Patients should be evaluated for peripheral access by the apheresis nurses, who will provide guidance on whether the patient is a candidate for peripheral access from their perspective. A 17-gauge to 18-gauge needle is adequate for return blood flows above 80 mL/min. 69 In patients without amenable peripheral access, a temporary double-lumen CVC is typically the best choice for vascular access. In the majority of cases, RBC exchange is done once, so the catheter can be removed after the procedure is complete. Patients who present in sickle cell crisis are often dehydrated, and their peripheral veins will collapse under the pressure of the blood draw; thus, a temporary CVC is ideal in this setting for RBC exchange as well as for hemodynamic support of a critical patient. IJ or subclavian venous catheters are generally preferable to femoral venous catheters (Table 2) . Temporary CVCs can be used for almost all hospitalized patients who require short-term (<2 weeks) RBC exchange. Tunneled catheters are considered the vascular access of choice when the anticipated duration of RBC exchange is between 2 weeks and a few months. Ports cannot be placed for urgent RBC exchange; however, they are a good option for outpatients on chronic RBC exchange. AV fistulae are considered the preferred vascular access for RBC exchange in patients with pre-existing fistulae for hemodialysis.
In infants and young children who require RBC exchange, peripheral access is not typically an option; catheters can withstand the negative pressure when drawing blood into the apheresis machine, and their gauge should be selected according to the patient's weight (Table 3) . 70 
Catheter complications and care
CVCs are associated with complications that include infections, bleeding, thrombosis, and vessel collapse. These complications are associated with factors that are either catheter-related or patient-related. 71 Catheterrelated infections are some of the most serious and common complications of CVCs. The risk of infection increases with indwelling time, 72 prolonged hospital stay, and improper catheter care and maintenance. 73 All hospitals and apheresis units should develop and follow strict guidelines for central catheter insertion, access, and care. Antibiotic-impregnated catheters have been used successfully 63, 74 ; however, their efficacy in reducing catheter-related infections in the setting of therapeutic apheresis has not been studied. The risk of infectious complications is substantially reduced with long-term catheters (tunneled catheters) or, to an even greater extent, with ports compared with CVCs. 63, 71, 75 Major bleeding from CVC insertion is uncommon, even in patients who have thrombocytopenia and coagulation disorders. 76 Catheter placement can be performed safely with platelet counts of 20 3 10 9 /L or greater. 77 This complication is less likely to be a problem in patients with SCD, who usually have normal or increased platelet counts. The severity of coagulopathy does not predict bleeding, and there is evidence to support the finding that no correction for an international normalized ratio up to 3.0 is needed before catheter insertion. 76 Thrombus formation is a major complication of the use of CVCs. Its incidence might be as high as 67% of patients when the indwelling time is 1 week or more 78 ; this high incidence includes patients who have asymptomatic catheter thrombosis detected by ultrasound. There is a strong correlation between catheter-related thrombosis and infections, but it is unclear which may predispose to the other. 79 Both catheter infections and thrombosis can cause catheter dysfunction. Prophylactic heparin administration decreases the risk of catheterrelated thrombus formation and infections. 80 CVC lumens can be occluded due to thrombus formation, which usually develops gradually, with intermittent resistance during catheter flushing until it becomes completely occluded. If change of posture does not enable blood aspiration, then thrombolytic agents, such as alteplase or urokinase, should be infused into the blocked catheter lumen. 81, 82 Insertion of CVCs should be performed or supervised by experienced physicians. The risk of mechanical complications significantly increases with more than three attempts at catheter insertion. 83 Permanent CVCs and ports can have immediate complications after insertion that include bleeding problems, pneumothorax, embolism, catheter tip malposition, and infections. 84 These early complications have dropped significantly with the use of ultrasound and fluoroscopic guidance. Late complications (after 30 days from placement) of ports are mostly limited to thrombotic and infectious problems. In one large study, perioperative complications of permanent ports occurred in 5.7% of patients and included catheter malposition (3.1%), pneumothorax (1.3%), and hemorrhage (0.9%). 85 Long-term complications occurred in 6.6% of patients and included infection (2.2%), thrombosis (1.3%), extravasation (1.3%), and catheter fracture (1.8%).
Published experience with children indicates that long-term apheresis can be provided through the regular high-flow ports used in adult patients. 86, 87 Different size dialysis catheters are used based on the weight of the patient. 70 In small children who require frequent RBC exchange, permanent ports are preferred to external central venous lines.
FUTURE DIRECTIONS
RBC exchange is an important treatment option for SCD and other entities, and additional potential clinical applications are actively being studied. RBC exchange could improve with a better understanding of therapeutic apheresis technology, vascular access, and patient variables that could affect RBC exchange efficacy. At the level of therapeutic apheresis devices and technology, patients and blood utilization could benefit from improved efficiency of the procedure itself, such as targeting diseased RBCs based on a defining feature that can be exploited by RBC exchange. At the vascular access level, research might benefit from new ports that can withstand high flow rates without affecting the hemodynamics of RBC exchange. In addition, our knowledge is lacking on how flow rate affects hemostasis; we have noticed in our practice that some patients undergoing RBC exchange develop thrombocytopenia and abnormal coagulation indices. Future studies might explain whether these findings are part of hemostatic system activation or due to high shearing stress caused by high flow rates. Continued studies in RBC exchange are clearly indicated for optimized care in patients who require the procedure.
CONCLUSIONS
In patients for whom RBC exchange is indicated, the choice of both exchange modality and vascular access should be considered carefully, particularly in those who receive treatment on a regular basis for SCD. Many options exist with unique benefits and risks. It is appropriate to monitor not just disease maintenance but also patient compliance with and complications of a chosen treatment modality and to adjust accordingly, including substituting a different form of vascular access. Providers should also be aware of new devices entering the market and should consider whether they may improve outcomes for their patients on an individual basis.
